

April 15, 2015



## **Medytox Solutions, Inc. Announces Results for the Year Ended December 31, 2014**

WEST PALM BEACH, FL -- (Marketwired) -- 04/15/15 -- Medytox Solutions, Inc. (OTCQB: MMMS) announced today its financial results for the year ended December 31, 2014 (the "2014 Year"). The Company reported net revenues of approximately \$57.9 million, which represented an increase of approximately \$16 million, or 38%, from the approximately \$41.9 million in net revenues reported for the year ended December 31, 2013 (the "2013 Year"). For the 2014 Year, the Company reported income from operations of approximately \$15.7 million, compared to income from operations of approximately \$14.5 million for the 2013 Year.

"Our 2014 results demonstrate a continued growth in revenue and earnings as a direct result of our investment in and commitment from an expanding and strong workforce and the demand for the Company's products and services in the healthcare sector," stated Seamus Lagan, the Company's Chief Executive Officer.

### ***About Medytox Solutions, Inc.***

Medytox Solutions, Inc. is a holding company that owns and operates businesses in the medical services sector. Medytox is a new generation healthcare enterprise that delivers a single source for integrated solutions. Medytox applies its innovative approach through an outstanding suite of IT & software solutions, revenue cycle management and financial services, combined with a range of diagnostic testing and other ancillary services for the healthcare sector. Its principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States.

### ***MEDYTOX SOLUTIONS, INC. & SUBSIDIARIES Consolidated Statements of Operations***

	<b><i>For the Year Ended December 31,</i></b>	
	<b><i>2014</i></b>	<b><i>2013</i></b>
<b><i>Revenues</i></b>		
Gross charges (net of contractual allowances and discounts)	<b>\$ 77,223,964</b>	<b>\$ 52,523,660</b>
Provision for bad debts	<b>(19,296,144)</b>	<b>(10,634,789)</b>
<b><i>Net Revenues</i></b>	<b>\$ 57,927,820</b>	<b>\$ 41,888,871</b>

**Operating expenses:**

Direct costs of revenue	15,920,468	9,570,950
General and administrative	19,712,018	13,479,879
Legal fees related to disputed subsidiary	94,217	976,789
Sales and marketing expenses	4,967,188	2,953,292
Bad debt expense	78,482	-
Depreciation and amortization	1,500,453	407,971
<b>Total operating expenses</b>	<b>42,272,826</b>	<b>27,388,881</b>
<b>Income from operations</b>	<b>15,654,994</b>	<b>14,499,990</b>
<b>Other income (expense):</b>		
Other income	489	389
Gain (Loss) on settlement of assets	-	(27,413)
Gain on disposition of subsidiary	134,184	-
Gain (Loss) on legal settlement	105,780	(169,800)
Interest expense	(513,815)	(474,649)
<b>Total other income (expense)</b>	<b>(273,362)</b>	<b>(671,473)</b>
<b>Income before income taxes</b>	<b>15,381,632</b>	<b>13,828,517</b>
Provision for income taxes	7,561,300	5,568,600
<b>Net income attributable to Medytox Solutions</b>	<b>7,820,332</b>	<b>8,259,917</b>
Preferred stock dividends	5,010,300	2,601,298
<b>Net income attributable to Medytox Solutions common shareholders</b>	<b>\$ 2,810,032</b>	<b>\$ 5,658,619</b>
<b>Net income per common share:</b>		
Basic	<b>\$ 0.09</b>	<b>\$ 0.19</b>
Diluted	<b>\$ 0.09</b>	<b>\$ 0.19</b>
<b>Weighted average number of common shares outstanding during the period:</b>		
Basic	<b>29,899,536</b>	<b>29,692,110</b>
Diluted	<b>30,924,538</b>	<b>30,160,335</b>

**"Forward-looking" Statements**

This press release may contain "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995, as amended. Any such statements are made pursuant to the safe-harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and they involve a number of risks and uncertainties that could cause actual results to differ materially from those that may be anticipated by or from the forward-looking statements. Important factors that could cause such a difference are set forth in the Company's filings with the Securities and Exchange Commission and include, but are not limited to, the ability to

consummate acquisitions and the ability to integrate such acquisitions.

***Medytox Solutions Contacts:***

Seamus Lagan  
CEO  
Medytox Solutions, Inc.  
561-855-1626

Sebastien Sainsbury  
Director, Investor Relations  
Medytox Solutions, Inc.  
561-666-9818  
[Email Contact](#)

Marilys Caraballo - Media  
[Email Contact](#)  
305-668-0070

Source: Medytox Solutions, Inc.